OP012: IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn’s disease patientsECCO '18 Vienna
2018
OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s diseaseECCO '18 Vienna
2018
OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for inflammatory bowel disease and irritable bowel syndromeECCO '18 Vienna
2018
OP015: Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALMECCO '18 Vienna
2018
OP016: Need for primary abdominal surgery, but not repeated surgery, has decreased: a nationwide study of temporal trends in Crohn surgery in Sweden 1990–2014ECCO '18 Vienna
2018
OP018: High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signallingECCO '18 Vienna
2018
OP020: The clinical determinants affect gut microbial profile of inflammatory bowel disease patientsECCO '18 Vienna
2018
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST studyECCO '18 Vienna
2018
OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD)ECCO '18 Vienna
2018
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II studyECCO '18 Vienna
2018
OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysisECCO '18 Vienna
2018
OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysisECCO '18 Vienna
2018
OP028: Single cell RNA sequencing of t-cells in Crohn’s disease identifies tissue specific drug targetsECCO '18 Vienna
2018